For the complement system to cause AMD, there must be initiation (a ‘trigger’), amplification, and local retinal damage caused by the process. The alternative pathway of the complement system is ...
Follow-up on phase 1 study of AT101, a novel anti-CD19 chimeric antigen receptor cell therapy (CAR-T) in patients with relapsed or refractory (r/r) b-cell non-Hodgkin lymphoma. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results